Tafenoquine Succinate Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg
Reference Brands: Krintafel (USA)
Category:
Antiemetic
Tafenoquine Succinate is available in Tablets
and strengths such as 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tafenoquine Succinate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tafenoquine Succinate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tafenoquine is a long-acting antimalarial medication used for both the prevention and treatment of malaria. It is especially important in the management of Plasmodium vivax malaria, where it is administered alongside a blood-stage antimalarial drug such as chloroquine to prevent disease relapse. Tafenoquine is also approved for malaria prophylaxis and can be used to help prevent all types of malaria in adults traveling to endemic regions.
The primary therapeutic advantage of tafenoquine lies in its ability to eliminate the dormant liver-stage parasites known as hypnozoites, which are responsible for recurrent infections caused by Plasmodium vivax and Plasmodium ovale. These hypnozoites can persist in the liver even after successful clearance of parasites from the bloodstream, leading to repeated episodes of malaria if not treated effectively. Tafenoquine belongs to the 8-aminoquinoline class of antimalarial agents and offers a significant benefit over primaquine, as it has a prolonged half-life of approximately two to three weeks, allowing for a single-dose treatment regimen rather than a 14-day course.
Due to the risk of hemolytic anemia, tafenoquine must only be used after confirming normal glucose-6-phosphate dehydrogenase (G6PD) activity. When prescribed appropriately, tafenoquine provides a convenient and effective option for the radical cure and prevention of relapsing malaria.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing